ClinicalTrials.gg

Program

ASK-120067

Also written as “ASK120067”, “ASKC202+ Limertinib” and “Rifampicin; ASK120067”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Beijing Aosaikang Pharmaceutical.

Furthest: phase 3, since Oct 12, 20195 company-led studies, 2 open or runningNext primary completion: Oct 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Aosaikang Pharmaceutical52 open or runningphase 3since Oct 12, 2019Apr 10, 2018Oct 31, 2027phase 3 · NCT07109531

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2018First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03502850 · 507 enrolled · China
  2. Oct 12, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04143607 · 337 enrolled · China
  3. Apr 20, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04360915 · 24 enrolled · China
  4. Nov 11, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05631678 · 48 enrolled · China
  5. Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531 · 286 planned · China

Ahead

  1. Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531

TargetBeta

EGFR →read by rule
“Limertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity.”study text, by rule · the study

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07109531Carcinoma, Non-Small-Cell Lung · China3RecruitingOct 31, 2027286
NCT05631678Carcinoma, Non-Small-Cell Lung · China1CompletedAug 3, 202248
NCT04360915Carcinoma, Non-Small-Cell Lung · China1CompletedDec 30, 201924
NCT04143607Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingMar 31, 2024337
NCT03502850Carcinoma, Non-Small-Cell Lung · China2UNKNOWNJan 2021507

How it is read

Names in the registry

  • “ASK120067”, 3 entries
  • “ASKC202+ Limertinib”, 1 entry
  • “Rifampicin; ASK120067”, 1 entry
  • “ASK120067;itraconazole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.